Literature DB >> 12511230

Metformin modulates insulin post-receptor signaling transduction in chronically insulin-treated Hep G2 cells.

Li Yuan1, Reinhard Ziegler, Andreas Hamann.   

Abstract

AIM: To study the effect of chronic insulin treatment on insulin post-receptor signaling transduction and whether the effects of metformin are transmitted throughout the cascade of insulin signaling intermediates in a human hepatoma cell line (Hep G2).
METHODS: Hep G2 cells were incubated in serum free media containing either insulin 100 nmol/L or insulin 100 nmol/L plus different concentrations (0.01-10 mmol/L) of metformin for 16 h and then were stimulated with insulin 100 nmol/L for 1 min.
RESULTS: Chronic treatment of insulin 100 nmol/L induced a significant reduction in the phosphorylation and protein expression of IR?, IRS1 and IRS2, which therefore resulted in a downregulation of association of PI3K with IRS. Therapeutic concentrations (0.01-0.1 mmol/L) of metformin prevented the changes induced by chronic insulin treatment in these post-receptor components of insulin signaling pathway. Tyrosine phosphorylation of IR?, IRS1, and IRS2 was increased by 2.7 fold (P < 0.01), 6.8 fold (P < 0.01), and 2.3 fold (P <0.01) of chronically insulin-treated cells alone, respectively, after metformin 0.1 mmol/L was added. The association of p85 with IRS1 and IRS2 was also increased from 34 % to 86 % (P <0.01) and from 30 % to 92 % (P <0.01), respectively. In contrast, metformin in pharmacological concentration (1-10 mmol/L) further inhibited tyrosine phosphorylation of IR?, IRS1, IRS2 and the interaction of PI3K with IRS. The association of IRS1 with p85 was further decreased by 58 % (P >0.05) and of IRS2 by 30 % (P <0.05).
CONCLUSION: Chronic insulin exposure of Hep G2 cells induces the downregulation of insulin signal transduction via PI3K pathway. The effect of metformin on insulin signaling transduction represent a primary mechanism of metformin action in insulin resistant state.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12511230

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  4 in total

1.  Metformin ameliorates IL-6-induced hepatic insulin resistance via induction of orphan nuclear receptor small heterodimer partner (SHP) in mouse models.

Authors:  Y D Kim; Y H Kim; Y M Cho; D K Kim; S W Ahn; J M Lee; D Chanda; M Shong; C H Lee; H S Choi
Journal:  Diabetologia       Date:  2012-02-21       Impact factor: 10.122

Review 2.  Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization.

Authors:  Takumi Kawaguchi; Michio Sata
Journal:  World J Gastroenterol       Date:  2010-04-28       Impact factor: 5.742

3.  NYGGF4 (PID1) effects on insulin resistance are reversed by metformin in 3T3-L1 adipocytes.

Authors:  Jie Qiu; Yu-Mei Wang; Chun-Mei Shi; Hong-Ni Yue; Zhen-Ying Qin; Guan-Zhong Zhu; Xin-Guo Cao; Chen-Bo Ji; Yan Cui; Xi-Rong Guo
Journal:  J Bioenerg Biomembr       Date:  2012-09-12       Impact factor: 2.945

Review 4.  Metformin: A Hopeful Promise in Aging Research.

Authors:  Marta G Novelle; Ahmed Ali; Carlos Diéguez; Michel Bernier; Rafael de Cabo
Journal:  Cold Spring Harb Perspect Med       Date:  2016-03-01       Impact factor: 6.915

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.